News: A concensus on the Rx for PCOS infertility


Treatment of infertility in women with polycyctic ovary syndrome (PCOS).

Experts from around the globe met recently in Greece to develop a consensus regarding treatment of infertility in women with polycystic ovary syndrome (PCOS).

They agreed that before considering medical treatment, physicians should counsel patients on the importance of lifestyle changes including weight reduction, exercise, smoking, and alcohol consumption.

They also agreed that treatment should be tailored to each patient's individual circumstances, but that generally first-line treatment should consist of the anti-estrogen clomiphene citrate (CC) for ovulation induction. If this fails to result in pregnancy, second-line treatment should consist of either exogenous gonadotropins with intense monitoring of ovarian response because of the high chance for multiple pregnancy or laparoscopic ovarian surgery. Because the latter as a lone method is effective in fewer than 50% of women, additional ovulation induction medication is usually required. Treatment with CC and gonadotropins is associated with a cumulative singleton live-birth rate of 72%. Third-line treatment should consist of in vitro fertilization.

Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505-522.

Recent Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit:
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit:
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
© 2024 MJH Life Sciences

All rights reserved.